Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting

What happened

Genmab said 22 abstracts on epcoritamab will be presented or published at the American Society of Hematology meeting on December 12–15, 2026. Six are oral presentations, including the first disclosure of primary results from a Phase 3 study testing epcoritamab with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.

Confirmed

Global impact / market context

The results could shape whether doctors and regulators see this treatment combination as useful for patients whose lymphoma has returned or resisted treatment. If later evidence supports broader use, demand could affect Genmab’s future sales and development spending; the article reports no results yet.

Analyst inference

The announcement concerns clinical evidence, not an approval or a sales update. The key near-term information is the Phase 3 study’s primary results, which could influence expectations for epcoritamab’s role in lymphoma treatment, but the article gives no efficacy, safety, or commercial figures.

Analyst inference

What to watch

1. At the December 12–15, 2026 meeting, watch for the primary results from the Phase 3 study of epcoritamab plus lenalidomide in relapsed or refractory lymphoma. Confirmed
2. Look for the reported benefits and risks, including how well the combination works and its side effects; the article does not yet provide those findings. Analyst inference
3. Further evidence in other lymphoma types or earlier treatment stages could clarify whether epcoritamab’s potential use extends beyond the patient group in the featured study. Analyst inference

Evidence

• globenewswire.com